Management of pulmonary toxicity associated with immune checkpoint inhibitors
Immunotherapy has become a standard of care in oncology, following the recent approvals of cytotoxic T-lymphocyte-associated protein-4 and programmed cell death-1 inhibitors in lung cancer, melanoma, renal cell carcinoma, Hodgkin's lymphoma, bladder, head and neck cancers. Besides their efficac...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2019-11-01
|
| Series: | European Respiratory Review |
| Online Access: | http://err.ersjournals.com/content/28/154/190012.full |